Jeffrey Schlom

Q: What Schools Are Affiliated With Jeffrey Schlom

Jeffrey Schlom is affiliated with the following schools: University of California, Berkeley, California Institute of Technology, Stanford University, Georgetown University, University of Colorado, Columbia University

Jeffrey Schlom's AcademicInfluence.com Rankings

Jeffrey Schlom

Chemistry

#1160

World Rank

#1821

Historical Rank

Nanotechnology

#37

World Rank

#37

Historical Rank

chemistry Degrees

Jeffrey Schlom

Engineering

#1810

World Rank

#2587

Historical Rank

Materials Science

#44

World Rank

#45

Historical Rank

Applied Physics

#168

World Rank

#177

Historical Rank

engineering Degrees

Download Badge

Chemistry
Engineering

Jeffrey Schlom's Degrees

PhD Physics Stanford University

Why Is Jeffrey Schlom Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jeffrey Schlom's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy (2006) (1381)
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. (2005) (936)
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. (1992) (865)
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. (2010) (836)
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. (1984) (600)
A spectrum of monoclonal antibodies reactive with human mammary tumor cells. (1981) (589)
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. (1995) (540)
Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes (2004) (512)
Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. (1986) (467)
External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing (2004) (438)
Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. (1986) (432)
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. (2000) (381)
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer (2005) (368)
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. (1991) (363)
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populations (1982) (338)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells (2015) (329)
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. (2012) (327)
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy (2002) (323)
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. (2000) (316)
In vivo tumor targeting of a recombinant single-chain antigen-binding protein. (1990) (311)
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. (2007) (307)
A triad of costimulatory molecules synergize to amplify T-cell activation. (1999) (302)
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. (2005) (301)
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. (2006) (289)
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity (2011) (286)
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer (2010) (284)
Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies (1986) (282)
Expression of ras oncogene p21 in prostate cancer. (1986) (265)
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. (1997) (264)
Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. (1980) (262)
Therapeutic cancer vaccines: current status and moving forward. (2012) (259)
Characterization of the Products of RNA-directed DNA Polymerases in Oncogenic RNA Viruses (1970) (257)
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. (2004) (247)
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. (2017) (241)
Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. (1983) (238)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors (2018) (234)
Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. (1984) (234)
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. (2010) (231)
Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases (1984) (231)
Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. (1986) (230)
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer (2002) (228)
Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. (1984) (225)
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. (1997) (222)
Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. (1983) (221)
Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma (2008) (220)
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. (1992) (217)
Cancer Vaccines: Moving Beyond Current Paradigms (2007) (213)
Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas (1983) (210)
Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement (2008) (210)
Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule (2000) (208)
Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. (1997) (207)
Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. (1999) (205)
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. (1999) (204)
Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. (1999) (201)
Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. (1985) (200)
Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. (1987) (196)
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. (2007) (192)
Simultaneous Detection of Reverse Transcriptase and High Molecular Weight RNA Unique to Oncogenic RNA Viruses (1971) (189)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations (2018) (186)
Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. (1994) (184)
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. (2001) (181)
Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. (1987) (180)
Synthetic DNA–RNA Hybrids and RNA–RNA Duplexes as Templates for the Polymerases of the Oncogenic RNA Viruses (1970) (178)
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer (2017) (178)
Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA (2003) (175)
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. (2000) (173)
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. (1997) (167)
Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. (1991) (165)
ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma (1985) (161)
Basic principles and applications of monoclonal antibodies in the management of carcinomas: the Richard and Hinda Rosenthal Foundation award lecture. (1986) (160)
The Human T-Box Mesodermal Transcription Factor Brachyury Is a Candidate Target for T-Cell–Mediated Cancer Immunotherapy (2007) (157)
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy (2007) (156)
RNA-dependent DNA Polymerase Activity in Virus-like Particles isolated from Human Milk (1971) (155)
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. (2001) (154)
Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody. (1985) (153)
Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer (2008) (149)
Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. (1988) (149)
Viral vector-based therapeutic cancer vaccines. (2011) (149)
Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. (1986) (149)
DNA-directed DNA Polymerase Activity in Oncogenic RNA Viruses (1970) (148)
Presence in Human Breast Cancer of RNA homologous to Mouse Mammary Tumour Virus RNA (1972) (145)
Immune response to a carcinoembryonic antigen polynucleotide vaccine. (1994) (144)
Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. (1986) (143)
Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. (1992) (141)
Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy (2008) (140)
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. (2019) (140)
Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. (1987) (140)
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. (1998) (140)
Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. (1985) (139)
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine (2018) (139)
Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. (1984) (138)
Effects of conventional therapeutic interventions on the number and function of regulatory T cells (2013) (137)
Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. (1990) (136)
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. (2001) (134)
Multiple Costimulatory Modalities Enhance CTL Avidity (2005) (133)
Strategies for Cancer Vaccine Development (2010) (133)
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances (2020) (133)
Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3 (1987) (131)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele (2016) (131)
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. (2002) (129)
Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules (2005) (129)
Monoclonal Antibody B72.3 Reactivity with Human Endometrium: A Study of Normal and Malignant Tissues (1987) (129)
Detection and cloning of human DNA sequences related to the mouse mammary tumor virus genome. (1982) (127)
Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC (2003) (127)
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors (2019) (126)
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas (2016) (126)
Clinical safety of a viral vector based prostate cancer vaccine strategy. (2007) (125)
Vaccine therapy of established tumors in the absence of autoimmunity. (2003) (123)
Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. (1993) (123)
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer (2011) (122)
Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy (2010) (122)
Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. (1994) (121)
Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. (2000) (120)
A radioimmunoassay for the detection of a human tumor‐associated glycoprotein (tag‐72) using monoclonal antibody B72.3 (1986) (118)
A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate (1995) (117)
Acquisition of CD80 (B7-1) by T Cells (2001) (116)
A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. (1999) (116)
Clinical trial designs for the early clinical development of therapeutic cancer vaccines. (2001) (115)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells (2017) (114)
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. (1996) (114)
Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer (2012) (114)
The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). (1986) (113)
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury (2015) (113)
Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer (2013) (112)
Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. (1989) (111)
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. (2002) (111)
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. (2002) (110)
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. (2005) (110)
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models (2019) (110)
Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. (1985) (109)
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. (2002) (109)
Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors (1987) (109)
Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. (1990) (108)
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. (2012) (106)
Expression in COS cells of a mouse-human chimaeric B72.3 antibody. (1987) (106)
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. (2011) (105)
Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. (1991) (105)
The immunocytokine NHS-IL12 as a potential cancer therapeutic (2014) (104)
Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. (1995) (103)
Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma. (1990) (102)
Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. (2009) (102)
Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases (2015) (102)
Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant (2008) (102)
Impact of tumour volume on the potential efficacy of therapeutic vaccines. (2011) (101)
Acquisition of CD80 by Human T Cells at Early Stages of Activation: Functional Involvement of CD80 Acquisition in T Cell to T Cell Interaction (2002) (100)
New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. (1987) (99)
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. (1983) (99)
Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. (1989) (98)
Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. (2000) (98)
Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. (1992) (97)
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. (1989) (97)
Differential binding to human mammary and nonmammary tumors of monoclonal antibodies reactive with carcinoembryonic antigen. (1983) (96)
The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors (2005) (95)
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates (2014) (94)
A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA) (1991) (93)
Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG‐72) (1986) (93)
Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. (1997) (93)
Phase II radioimmunotherapy trial with 131I‐CC49 in colorectal cancer (1994) (92)
Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD‐L1 and the PD‐L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD‐L1 Antibody Avelumab (2016) (92)
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer (2002) (92)
Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. (1995) (92)
Agonist peptide from a cytotoxic t‐lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1‐type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide (2000) (91)
Major pol gene progenitors in the evolution of oncoviruses. (1984) (91)
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma (2014) (89)
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. (1992) (88)
Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. (1995) (88)
The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines (2000) (88)
Vaccination with a Recombinant Saccharomyces cerevisiae Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses (2008) (88)
Mutant ras epitopes as targets for cancer vaccines. (1996) (88)
Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3. (1988) (87)
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab (2016) (87)
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. (2002) (87)
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. (2001) (86)
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells (2016) (86)
Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis (2006) (86)
Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. (1999) (85)
Clinical evaluation of TRICOM vector therapeutic cancer vaccines. (2012) (84)
Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. (2001) (84)
Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. (2003) (84)
Induction of an Antigen Cascade by Diversified Subcutaneous/Intratumoral Vaccination Is Associated with Antitumor Responses (2005) (83)
A new class of endogenous human retroviral genomes. (1985) (83)
SDR grafting--a new approach to antibody humanization. (2005) (82)
Monoclonal antibodies to the human laminin receptor recognize structurally distinct sites. (1985) (81)
Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. (2006) (80)
Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. (1997) (79)
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma (2019) (78)
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. (1992) (77)
The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line. (1995) (76)
Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. (1992) (76)
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors (2018) (74)
Detection of High-Molecular-Weight RNA in Particles from Human Milk (1972) (74)
Secretion of a single-gene-encoded immunoglobulin from myeloma cells. (1993) (74)
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1 (2018) (74)
Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. (1997) (74)
Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. (1996) (74)
Isolation and characterization of a new type D retrovirus from the asian primate, Presbytis obscurus (spectacled langur). (1978) (74)
Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens. (1986) (73)
Combination of a Poxvirus-Based Vaccine with a Cyclooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor Immunity and Long-Term Survival in CEA.Tg/MIN Mice (2004) (72)
Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint Inhibitor (2016) (72)
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody (2017) (71)
Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. (2001) (71)
Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. (1992) (71)
Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization. (1987) (70)
Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis. (2014) (70)
Ca 72‐4 radioimmunoassay for the detection of the tag‐72 carcinoma‐associated antigen in serum of patients (1989) (69)
Cancer vaccines: preclinical studies and novel strategies. (2006) (69)
Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. (2015) (69)
Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). (1999) (69)
Carcinoembryonic antigen as a target for cancer vaccines (1996) (69)
Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. (1984) (68)
Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. (1999) (67)
High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. (2000) (67)
Relationship in nucleic acid sequences between mouse mammary tumor virus variants. (1975) (66)
Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. (2008) (65)
Co‐expression of human cancer‐associated epitopes on mucin molecules (1987) (65)
A CDR-grafted (humanized) domain-deleted antitumor antibody. (1997) (65)
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. (1998) (65)
Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. (1987) (65)
Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12 (2010) (65)
Chitosan solution enhances the immunoadjuvant properties of GM-CSF. (2007) (65)
DNA polymerase activities in varions of visna virus, a causative agent of a "slow" neurological disease. (1971) (65)
Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin (2005) (65)
Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody (2016) (64)
Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses (1996) (64)
Differential effects of recombinant human leukocyte interferons on cell surface antigen expression. (1986) (64)
Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. (1995) (63)
Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. (1996) (63)
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations (2020) (62)
IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines. (2001) (62)
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine (2013) (62)
Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B72.3. (1984) (61)
Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon. (1993) (61)
Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlation (1997) (60)
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies (2020) (60)
The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell–Mediated Killing (2008) (60)
In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. (2001) (59)
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy (2019) (58)
A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients (2010) (58)
Biochemical and morphologic evidence for the presence of an RNA tumor virus in pulmonary carcinoma of sheep (Jaagsiekte). (1974) (57)
Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only (2000) (57)
Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human gamma-interferon. (1989) (57)
Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses (2010) (57)
Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. (2001) (56)
Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas. (1987) (56)
TAG‐72 (CA 72‐4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer (1993) (55)
Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies (1989) (55)
Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity (2013) (55)
Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. (2002) (54)
Tumor‐associated glycoprotein (TAG‐72) detected in adenocarcinomas and benign lesions of the stomach (1986) (54)
Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. (2004) (54)
Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. (1990) (54)
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. (1990) (54)
Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. (2009) (53)
A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1 (2004) (53)
The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. (1999) (53)
Minimizing the Immunogenicity of Antibodies for Clinical Application (2005) (53)
Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. (2014) (53)
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination (2011) (53)
Synergistic Effects of IL-6 and IFN-γ on Carcinoembryonic Antigen (CEA) and HLA Expression by Human Colorectal Carcinoma Cells: Role for Endogenous IFN-β (1995) (52)
Complementation of anti‐CEA and anti‐TAG‐72 monoclonal antibodies in reactivity to human gastric adenocarcinomas (1987) (52)
Vaccines with Enhanced Costimulation Maintain High Avidity Memory CTL1 (2005) (52)
Single chain antigen binding protein (sFv CC49) (1997) (51)
A comparative study of the biologic and molecular basis of murine mammary carcinoma: a model for human breast cancer. (1973) (51)
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. (2007) (51)
Quantitation of RNA Tumor Viruses and Viruslike Particles in Human Milk by Hybridization to Polyadenylic Acid Sequences (1973) (51)
Biological and biochemical evidence for an interaction between Marek's disease herpesvirus and avian leukosis virus in vivo. (1973) (51)
In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. (2011) (51)
Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. (1989) (51)
The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. (2001) (50)
Paradigm Shifts in Cancer Vaccine Therapy (2008) (50)
TRICOM vector based cancer vaccines. (2006) (49)
Costimulatory molecules as adjuvants for immunotherapy. (2006) (49)
Peptide‐specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K‐ras p21 (1995) (49)
Histologic demonstration of antigens reactive with anti-p21 ras monoclonal antibody (RAP-5) in human stomach cancers. (1986) (48)
Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs. (2005) (48)
Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies. (1990) (48)
Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. (1997) (48)
A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses (2016) (48)
Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury (2017) (48)
Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes. (2000) (48)
Synthesis of 1-(p-Isothiocyanatobenzyl) Derivatives of DTPA and EDTA. (1986) (47)
Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. (1996) (47)
Intratumoral Vaccination and Diversified Subcutaneous/ Intratumoral Vaccination with Recombinant Poxviruses Encoding a Tumor Antigen and Multiple Costimulatory Molecules (2004) (47)
Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules (2005) (47)
Isolation of the mouse mammary tumor virus sequences not transmitted as germinal provirus in the C3H and RIII mouse strains (1977) (47)
DNA polymerase activities and nucleic acid components of virions isolated from a spontaneous mammary carcinoma from a rhesus monkey. (1971) (46)
Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. (2002) (46)
Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. (1994) (46)
Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice. (2008) (45)
Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF (2013) (45)
Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3. (1986) (45)
Squirrel monkey retrovirus: an endogenous virus of a new world primate (1977) (45)
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects (2008) (44)
Detection of carcinoembryonic antigen and related antigens in sera of patients with gastrointestinal tumors using monoclonal antibodies in double-determinant radioimmunoassays. (1983) (44)
Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies. (2002) (44)
Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity (2020) (44)
Definition of the expression of the human carcinoembryonic antigen and non‐specific cross‐reacting antigen in human breast and lung carcinomas (2009) (44)
Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types (2016) (44)
Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum (1987) (44)
SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. (2004) (43)
An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression (2018) (43)
Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein. (1995) (43)
Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. (1996) (43)
Coordinate elevation of serum markers in ovarian cancer but not in benign disease (1991) (43)
Monoclonal antibodies to breast cancer‐associated antigens as potential reagents in the management of breast cancer (1984) (43)
A biochemical approach to the study of the transmission of mouse mammary tumor viruses in mouse strains RIII and C3H (1976) (43)
Intraoperative radioimmunolocalization of colorectal carcinoma with a hand‐held gamma probe and MAb B72.3: Comparison of in vivo gamma probe counts with in vitro MAb radiolocalization (1988) (43)
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types (2018) (43)
Reverse transcriptase and high molecular weight RNA in particles from mouse and human milk. (1972) (43)
IL-2/Anti-IL-2 Antibody Complex Enhances Vaccine-Mediated Antigen-Specific CD8+ T Cell Responses and Increases the Ratio of Effector/Memory CD8+ T Cells to Regulatory T Cells1 (2008) (42)
Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody (2017) (42)
Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. (2014) (42)
Further evidence for oncornaviruses in human milk: the production of cores. (1973) (42)
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF (2014) (42)
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine (2020) (42)
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. (2006) (41)
Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. (1996) (41)
Type-specific antigenic determinants on the major external glycoprotein of high- and low-oncogenic murine mammary tumor viruses (1977) (41)
Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. (2001) (41)
Effect of a small molecule BCL‐2 inhibitor on immune function and use with a recombinant vaccine (2010) (41)
Virus-related RNA in human and mouse mammary tumors. (1972) (41)
Therapeutic Vaccines for HPV-Associated Malignancies (2020) (40)
Induction of Higher-Avidity Human CTLs by Vector-Mediated Enhanced Costimulation of Antigen-Presenting Cells (2005) (40)
Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. (1991) (40)
Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations (2010) (40)
Tumor‐associated glycoprotein‐72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A lingitudinal study (1991) (40)
The immunohistochemical reactivity of a human monoclonal antibody with tissue sections of human mammary tumors (1982) (39)
Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons. (1991) (39)
Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. (2018) (39)
Evidence for translation of viral-specific RNA in cells of a mouse mammary carcinoma. (1972) (39)
Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties. (1998) (38)
Use of monoclonal antibodies to define the diversity of mammary tumor viral gene products in virions and mammary tumors of the genus Mus. (1981) (38)
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. (2017) (38)
Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody. (1988) (38)
Characterization of mouse mammary tumor viruses propagated in heterologous cells. (1977) (38)
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules (2019) (38)
Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. (1998) (38)
International Meeting on Cancer Vaccines (2004) (38)
Biologic properties of a Ch2 domain‐deleted recombinant immunoglobulin (1993) (38)
Monoclonal antibodies and breast cancer. (1986) (38)
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design (2010) (37)
Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy (2004) (37)
Potential clinical utility of monoclonal antibodies in the management of human carcinomas. (1985) (37)
Translational Research Working Group Developmental Pathway for Immune Response Modifiers (2008) (37)
The effects of induction conditions on production of a soluble anti-tumor sFv in Escherichia coli. (1994) (37)
ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti‐PD‐L1 antibody (2017) (37)
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer (2013) (36)
The Use of a Cationic Liposome Formulation (DOTAP) Mixed with a Recombinant Tumor‐Associated Antigen to Induce Immune Responses and Protective Immunity in Mice (1998) (36)
Mason-Pfizer monkey virus: analysis and localization of virion proteins and glycoproteins (1975) (36)
Rationale for IL-15 superagonists in cancer immunotherapy (2020) (36)
Exercise enhances vaccine-induced antigen-specific T cell responses. (2008) (36)
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial (2016) (36)
Biochemical properties of the bromodeoxyuridine-induced guinea pig virus (1975) (36)
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses (2007) (36)
Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody (2002) (36)
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer (2020) (36)
Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons. (1988) (35)
Strain-specific markers for the major structural proteins of highly oncogenic murine mammary tumor viruses by tryptic peptide analyses (1978) (35)
Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3. (1986) (35)
The expression of colorectal carcinoma-associated antigens in the normal colonic mucosa. An immunohistochemical analysis of regional distribution. (1989) (35)
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824) (2017) (35)
Correlation of DNA hypomethylation with expression of carcinoembryonic antigen in human colon carcinoma cells. (1988) (35)
Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. (2005) (34)
Overcoming hypoxia-induced functional suppression of NK cells (2020) (34)
Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. (1985) (34)
Use of monoclonal antibodies to human breast‐tumor‐associated antigens in fine‐needle aspirate cytology (1986) (34)
Monoclonal antibodies reactive with breast tumor-associated antigens. (1985) (34)
Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. (1999) (34)
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies (2018) (34)
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. (2005) (34)
CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. (1999) (34)
Independent polypeptide chain initiation sites for the synthesis of different classes of proteins for an RNA tumor virus: mouse mammary tumor virus. (1976) (34)
Tumor markers as targets for selective diagnostic and therapeutic procedures. (1996) (34)
Specific Immunotherapy Using a Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen (1993) (34)
Tumor‐associated glycoprotein (TAG‐72) expression in ulcerative colitis (1989) (34)
Generation and Characterization of a Recombinant/Chimeric B72.3 (Human γ1) (1991) (33)
Tumor targeting with monoclonal antibody B72.3. (1989) (33)
Efficient ADCC- killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. (2019) (33)
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy (2009) (33)
Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. (2009) (33)
Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide‐labeled immunoconjugates (1994) (33)
A novel monoclonal antibody design for radioimmunotherapy. (2003) (33)
Multiple antigenic determinants on the major surface glycoprotein of murine mammary tumor viruses. (1977) (33)
Augmentation of tumor antigen expression by recombinant human interferons: enhanced targeting of monoclonal antibodies to carcinomas. (1990) (32)
Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. (1994) (32)
Effect of recombinant α-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer : A phase II trial (1997) (32)
Immunization with a Syngeneic Tumor Infected with Recombinant Vaccinia Virus Expressing Granulocyte‐Macrophage Colony‐Stimulating Factor (GM‐CSF) Induces Tumor Regression and Long‐Lasting Systemic Immunity (1997) (32)
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer (2019) (32)
Surface expression of tumor-associated antigens in primary cultured human colonic epithelial cells from carcinomas, benign tumors, and normal tissues. (1985) (32)
Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: Follow-up clinical results from ECOG 7897 (2005) (32)
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. (2004) (31)
The diversity of T‐cell co‐stimulation in the induction of antitumor immunity (1999) (31)
Up‐regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration‐resistant prostate cancer (2013) (31)
Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. (1996) (31)
Differential expression of carcinoembryonic antigen in early gastric adenocarcinomas versus benign gastric lesions defined by monoclonal antibodies reactive with restricted antigen epitopes. (1987) (31)
Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells (2011) (31)
Therapeutic cancer vaccines. (2014) (31)
Targeting cancer with radiolabeled antibodies. (1995) (31)
Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process. (2014) (31)
The role of soluble CD40L in immunosuppression (2013) (30)
Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus. (1999) (30)
TGF-β modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression (2009) (30)
Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. (1997) (30)
A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production. (2003) (30)
Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). (2010) (29)
Rational antigen modification as a strategy to upregulate or downregulate antigen recognition. (2000) (29)
Characterization of visna virus nucleic acid (1971) (29)
Tumor-Induced Impairment of TCR Signaling Results in Compromised Functionality of Tumor-Infiltrating Regulatory T Cells1 (2008) (29)
Intraoperative radioimmunodetection of ovarian cancer using monoclonal antibody B72.3 and a portable gamma‐detecting probe (1990) (29)
A monoclonal antibody (D612) with selective reactivity for malignant and normal gastro‐intestinal epithelium (1989) (28)
In Vitro and in Vivo Regulation of Human Tumor Antigen Expression by Human Recombinant Interferons: A Review (1994) (28)
Distribution of Mason-Pfizer Virus-Specific Sequences in the DNA of Primates (1977) (28)
Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters. (1989) (28)
Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy (2016) (28)
A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. (2013) (27)
ras oncogene p21 as a tumor marker in the cytodiagnosis of gastric and colonic carcinomas (1987) (27)
Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy (2014) (27)
Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man. (1989) (27)
Expression of a tumor-reactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery. (1995) (27)
Radioimmunoassays that demonstrate type-specific and group-specific antigenic reactivities for the major internal structural protein of murine mammary tumor viruses. (1978) (27)
Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells. (1992) (27)
Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN-beta. (1995) (27)
Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms (1987) (26)
The use of lymphocytes from axillary lymph nodes of mastectomy patients to generate human monoclonal antibodies. (1981) (26)
Avelumab in metastatic castration-resistant prostate cancer (mCRPC). (2017) (26)
Enhanced Functionality of CD 4 + CD 25 highFoxP 3 + RegulatoryTCells in the Peripheral Blood of Patients with Prostate Cancer (2008) (26)
An immunohistochemical analysis of ras oncogene expression in epithelial neoplasms of the colon (1990) (26)
Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast. (1987) (26)
Characterization of mouse mammary tumor viruses from primary tumor cell cultures. II. Biochemical and biophysical studies. (1976) (26)
Human cancer and animal viral oncology (1974) (26)
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic (2015) (25)
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas (2016) (25)
Vaccines as an Integral Component of Cancer Immunotherapy. (2018) (25)
Comparative studies on the expression of tumor‐associated glycoprotein (TAG‐72), CA 19‐9 and DU‐pan‐2 in normal, benign and malignant pancreatic tissue (1988) (25)
Isolation of host-range variants of mouse mammary tumor viruses that efficiently infect cells in vitro. (1978) (25)
Inhibition of TGF-β1 Signaling Promotes Central Memory T Cell Differentiation (2013) (25)
The Antitumor and Immunoadjuvant Effects of IFN-α in Combination with Recombinant Poxvirus Vaccines (2009) (25)
Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice (2010) (25)
A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC). (2011) (24)
T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors (2000) (24)
Combining Vaccines with Conventional Therapies for Cancer. (2007) (24)
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis (2019) (24)
In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. (2003) (24)
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein (2014) (24)
Immunotherapy biomarkers 2016: overcoming the barriers (2017) (24)
Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials. (1997) (24)
Expression of colorectal carcinoma-associated antigens in colonic polyps. (1993) (24)
Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis. (2007) (24)
Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody (2014) (23)
Applications of immunocytochemistry to clinical cytology. (1987) (23)
Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. (2002) (23)
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy (2016) (23)
Biochemical characterization of putative subviral particulates from human malignant breast tumors. (1975) (23)
The use of a panel of monoclonal antibodies in the evaluation of cytologic specimens from the central nervous system. (1987) (23)
Strategies in the development of recombinant vaccines for colon cancer. (1999) (23)
Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer (2005) (23)
A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. (1993) (23)
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells (2020) (23)
Sequence homology between the RNA of Mason-Pfizer monkey virus and the RNA of human malignant breast tumors. (1974) (23)
Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. (2003) (22)
Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis (2014) (22)
New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma. (1991) (22)
A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma. (1990) (22)
Vaccines and Immunostimulants (2003) (22)
In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand (1998) (22)
Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2 (2007) (22)
Monoclonal antibodies in gastrointestinal cancers. (1988) (22)
The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents (2020) (22)
Characterization of mouse mammary tumor viruses from primary tumor cell cultures.I. Immunologic and structural studies. (1976) (22)
Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts. (1989) (21)
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver (2011) (21)
Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. (1990) (21)
Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). (2001) (21)
Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment (2021) (21)
Improved Tumor Radioimmunodetection Using a Single-Chain Fv and γ-Interferon: Potential Clinical Applications for Radioimmunoguided Surgery and γ Scanning (1995) (21)
Interspecies radioimmunoassay for the major structural proteins of primate type-D retroviruses. (1977) (21)
Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity (2007) (21)
OA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs) (2017) (21)
The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex (2018) (21)
Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors. (2015) (21)
Innovations in monoclonal antibody tumor targeting. Diagnostic and therapeutic implications. (1989) (20)
Serological analysis of reverse transcriptase of the Mason-Pfizer monkey virus. (1974) (20)
Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. (2011) (20)
Isolation of a series of novel variants of murine mammary tumor viruses with broadened host ranges (1980) (20)
Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. (2018) (20)
The relationship of visna, maedi and RNA tumor viruses as studied by molecular hybridization. (1973) (20)
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve (2021) (20)
Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients. (1987) (20)
Identification of cytotoxic T‐lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4) (2007) (20)
Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients (2009) (20)
Synergistic antitumor activity of immune strategies combined with radiation. (2007) (20)
Current status of radioimmunotherapy. (1994) (20)
The coming of age of cancer radioimmunoconjugates. (1993) (20)
Baculovirus recombinants expressing the human carcinoembryonic antigen gene. (1993) (20)
Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers. (2018) (19)
Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity. (1987) (19)
Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy (2019) (19)
Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). (2009) (19)
HUMAN IMMUNE RESPONSE TO CARCINOEMBRYONIC ANTIGEN TUMOR VACCINES (1995) (19)
Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases. (1989) (19)
In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. (1999) (19)
RNA subunit structure of Mason-Pfizer monkey virus (1975) (19)
Expression of tumor-associated glycoprotein 72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. (1995) (18)
Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay. (1996) (18)
Modulation of human tumor antigen expression. (1987) (18)
Molecular Cloning and Characterization of the Complementary DNA of an Mr 110,000 Antigen Expressed by Human Gastric Carcinoma Cells and Upregulated by γ-Interferon (1994) (18)
Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2009) (18)
Recombinant chimeric monoclonal antibodies. (1990) (18)
Characterization of a new virus from Mus cervicolor immunologically related to the mouse mammary tumor virus. (1978) (18)
Detection of adenocarcinoma in peritoneal washings by staining with monoclonal antibody B72.3. (1989) (18)
Actinium-225 Conjugates of MAb CC49 and Humanized ΔCH2CC49 (2002) (18)
Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer. (1999) (18)
Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients (2005) (18)
Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells. (2010) (17)
In situ detection of c-myc mRNA in adenocarcinomas, adenomas, and mucosa of human colon. (1989) (17)
ABO blood type correlates with survival on prostate cancer vaccine therapy (2015) (17)
Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. (2001) (17)
Recent advances in therapeutic cancer vaccines. (2012) (17)
Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. (2019) (17)
Potential for recombinant immunoglobulin constructs in the management of carcinoma (1994) (17)
Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens. (1996) (17)
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy (2019) (17)
Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12 (2019) (17)
Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma (2021) (17)
Isolation and characterization of a new mouse mammary tumor virus from BALB/c mice. (1981) (17)
A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. (2017) (17)
Differences in mouse mammary tumor viruses: Relationship to early and late occurring mammary tumors (1977) (17)
Improved experimental radioimmunotherapy of colon xenografts by combining131I-CC49 and Interferon-γ (1994) (16)
Tumor-associated antigen TAG-72: Correlation of expression in primary and metastatic breast carcinoma lesions (2005) (16)
Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody. (1999) (16)
Clinical evaluation of CA72-4 immunoradiometric assay for serum TAG-72 antigen in patients with carcinoma (1990) (16)
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) (2021) (16)
Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. (2006) (16)
Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. (2017) (16)
IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy (2010) (16)
Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow (1988) (16)
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. (2019) (16)
Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. (1999) (16)
Identification of a novel tumor-associated Mr 110,000 gene product in human gastric carcinoma cells that is immunologically related to carcinoembryonic antigen. (1991) (15)
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells (2014) (15)
A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. (2018) (15)
PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment (2014) (15)
Immunological characterization of a novel human colon‐associated antigen (CAA) by a monoclonal antibody (1987) (15)
Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design (2008) (15)
Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer. (2015) (15)
Preferential use of a H chain V region in antitumor-associated glycoprotein-72 monoclonal antibodies. (1993) (15)
Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape (2021) (15)
Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens. (2003) (15)
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist (2020) (15)
The Use of a Humanized NSG-β2m−/− Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa (2020) (15)
Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors. (2017) (15)
Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). (1993) (14)
A phase I study of sequential vaccinations with recombinant Fowlpox-PSA (L155)-TRICOM (rF)alone, or in combination with recombinant vaccinia-PSA (L155)-TRICOM (rV), and the role of GM-CSF, in patients (Pts) with prostate cancer. (2004) (14)
Distinct Effects of Saracatinib on Memory CD8+ T Cell Differentiation (2012) (14)
Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. (1993) (14)
TAG-72 expression and its role in the biological evaluation of human colorectal cancer. (1996) (14)
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells (2021) (14)
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. (2012) (14)
Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. (2001) (14)
Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. (2012) (14)
Purification and characterization of the RNA-directed DNA polymerase of a primate type-D retrovirus: Mason-Pfizer virus. (1980) (14)
Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer. (2015) (14)
Immunohistochemical analysis of normal and mutated ras oncogene p21 expression in human pulmonary and pleural neoplasms (1988) (13)
Vaccination with a recombinant vaccinia vaccine containing the B7‐1 co‐stimulatory molecule causes no significant toxicity and enhances T cell–mediated cytotoxicity (2000) (13)
Self-reactive antibody expression by human carcinoma cells engineered with monoclonal antibody genes. (1993) (13)
Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity. (2008) (13)
Radioimmunoassays for the 36,000-dalton glycoprotein of murine mammary tumor viruses demonstrate type, group, and interspecies determinants (1979) (13)
Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs). (2016) (13)
Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies (2019) (13)
Evidence for viral involvement in murine and human mammary adenocarcinoma. (1973) (13)
NHS-IL12, a Tumor-Targeting Immunocytokine (2021) (13)
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. (1997) (13)
General keynote: vaccine strategies for the therapy of ovarian cancer. (2003) (13)
Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer (2017) (13)
Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies (2005) (13)
Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612. (1991) (13)
Analysis of ras oncogene products by two-dimensional gel electrophoresis: evidence for protein families with distinctive molecular forms. (1986) (13)
A Triad of Costimulatory Molecules Synergize to Amplify T‐‐Cell Activation in Both Vector‐‐Based and Vector‐‐Infected Dendritic Cell Vaccines (2003) (13)
Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication (2022) (13)
Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies. (2021) (12)
Human Lymphokine-Activated Killer Cells Augment Immunotherapy of Human Colon Carcinoma Xenografts with Monoclonal Antibody D612 (1991) (12)
Noncoordinate expression of murine mammary tumor virus gene products. (1980) (12)
Monoclonal antibodies to human mammary carcinoma associated antigens and their potential uses for diagnosis, prognosis, and therapy. (1983) (12)
A randomized pilot study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen independent prostate cancer. (2006) (12)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring (2011) (12)
Evidence for the rapid decrease in leukemogenic potential Rauscher leukemia virus in cell culture. (1971) (12)
Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. (1995) (12)
Phenotypic heterogeneity of a tumor-associated antigen in adenocarcinomas of the colon and their metastases as demonstrated by monoclonal antibody B72.3. (1986) (12)
Enhanced Levels of Costimulation Lead to Reduced Effector/Memory CD8+ T Cell Functionality1 (2007) (12)
Sialylatin of glycoproteins of murine mammary tumor virus, murine leukemia virus, and Mason-Pfizer monkey virus (1976) (12)
Carcinoembryonic antigen regulation in human colorectal tumor cells by a site‐selective cyclic amp analogue: A comparison with interferon‐gamma (1991) (12)
Immunological and structural relationships between langur virus and other primate type-D retroviruses. (1978) (12)
Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells. (1998) (11)
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer (2021) (11)
Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy (2012) (11)
Antigenic analysis of the major structural protein of the Mason-Pfizer monkey virus. (1976) (11)
Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas (1991) (11)
Generation, purification, and characterization of a recombinant source of human prostate‐specific antigen (1995) (11)
Absolute values of ras p21 defined by direct binding liquid competition radioimmunoassays. (1987) (11)
Combination therapies utilizing neoepitope-targeted vaccines (2020) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Detection of novel murine mammary tumor viruses by interspecies immunoassays. (1980) (11)
Role of vaccine therapy in cancer: biology and practice (2007) (11)
Lymphokine‐activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612 (1990) (11)
Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. (1994) (11)
Diversity of mammary tumor viral genes within the genus Mus, the species Mus musculus, and the strain C3H (1979) (11)
Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide. (2003) (11)
Tumor targeting with monoclonal antibody B72.3: experimental and clinical results. (1990) (11)
Comparison of the interferon-gamma-mediated regulation of tumor-associated antigens expressed by human gastric carcinoma cells. (1993) (10)
Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells. (1995) (10)
Biological response modifiers as adjuvants in monoclonal antibody-based treatment (review). (1993) (10)
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. (2007) (10)
Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant (2005) (10)
Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer (2010) (10)
Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management (2020) (10)
Vaccine Clinical Trials (2003) (10)
In vitro and in vivo regulation of tumor antigen expression by human recombinant interferons. (1991) (10)
Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49. (2002) (10)
First-in-human phase I trial of NHS-IL12 in advanced solid tumors. (2012) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients. (1995) (10)
A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG. (2014) (9)
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer (2003) (9)
Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression. (1993) (9)
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer (2021) (9)
Expression of ras oncogene p21 during human fetal development as determined by monoclonal antibodies RAP-5, Y13-259, and DWP (1988) (9)
Interspecies radioimmunoassay for the major internal protein of mammary tumor viruses. (1980) (9)
Potential for Artifacts in Monitoring for the Detection of Tumor Associated Antigens (TAG-72 and CEA) in Serum from Patients Undergoing MAb-based Diagnostic and Therapeutic Protocols (1990) (9)
Molecular Profile, Tissue Distribution and Prognostic Evaluation of a Human Melanoma-Carcinoma Antigen Recognized by the Murine Monoclonal Antibody B1.1 (1988) (9)
Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. (2013) (9)
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer (2020) (9)
Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. (1993) (9)
A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. (2013) (9)
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. (2013) (9)
Construction of phosphorylatable chimeric monoclonal antibody CC49. (1998) (9)
957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1 (2021) (8)
Generation and characterization of a single-gene encoded single-chain immunoglobulin-interleukin-2 fusion protein. (1995) (8)
In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72. (1991) (8)
The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic (2015) (8)
Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune–Tumor Interactions: Engage, Expand, Enable (2020) (8)
Immunological and pathological manifestations of murine sarcoma virus (Moloney) infections. (1970) (8)
Oral immunization with enterocoated microbeads induces antigen-specific cytolytic T-cell responses. (1998) (8)
NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma. (2014) (8)
Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009 (2021) (8)
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer (2022) (8)
Molecular cloning and characterization of the complementary DNA of an M(r) 110,000 antigen expressed by human gastric carcinoma cells and upregulated by gamma-interferon. (1994) (8)
Complementation of Expression of Carcinoembryonic Antigen and Tumor Associated Glycoprotein-72 (TAG-72) in Human Colon Adenocarcinomas (1991) (8)
Human Breast Cancer Markers Defined by Monoclonal Antibodies (1985) (8)
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis (2021) (8)
Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49. (1994) (7)
Serological and biochemical characterization of recombinant baculovirus carcinoembryonic antigen. (1994) (7)
Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein (2017) (7)
Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells (2009) (7)
Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon (2004) (7)
A human T cell line engineered to secrete chimeric monoclonal antibody. (1993) (7)
Development of quantitative liquid competition radioimmunoassays for the ras oncogene and proto‐oncogene p21 products (1986) (7)
Clinical evaluation of serum tumor‐associated glycoprotein‐72 as a novel tumor marker for colorectal cancer patients (1991) (7)
A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma. (2020) (7)
Construction and purification of domain-deleted immunoglobulin variants of the recombinant/chimeric B72.3 (y1) monoclonal antibody. (1993) (7)
Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene. (1994) (7)
Clinical evaluation of the new tumor marker TAG-72. (1991) (7)
Differential Distribution of Mouse Mammary Tumor Virus-Related Sequences in the DNA’s of Rats (1979) (7)
Assay for the detection of anti‐idiotypic antibodies to monoclonal antibody b72.3 (1990) (7)
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. (2022) (7)
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1) (2022) (6)
IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM A RANDOMIZED PHASE 2 CLINICAL TRIAL: MP15‐10 (2017) (6)
PHASE II TRIAL OF 131I-CC49 Mab PLUS ALPHA INTERFERON (rIFNα) IN BREAST CANCER (1994) (6)
DIVERSITY OF MOUSE MAMMARY TUMOR VIRUS GENETIC INFORMATION AND GENE PRODUCTS IN RODENTS (1978) (6)
Immunology of Lynch Syndrome (2021) (6)
Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells (2015) (6)
Monoclonal Antibodies in Immunoenzyme Studies of Breast Cancer a (1983) (6)
Phase I study of recombinant carcinoembryonic antigen (CEA) vaccinia virus vaccine with post vaccination carcinoembryonic antigen peptide (CAP-1) boost. (2000) (6)
Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy (2021) (6)
Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview. (1990) (6)
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa (2022) (6)
Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer. (2016) (6)
A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma. (2014) (6)
Abstract P5-16-06: A phase 2 randomized trial of docetaxel (DOC) alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM (PANVAC) (2012) (6)
Biochemical properties of the B-type retravirus of guinea pigs and an agent in the plasma of guinea pigs with L2C leukemia. (1977) (6)
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. (2003) (6)
Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies. (1992) (6)
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy (2021) (6)
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer (2021) (6)
PANVAC vaccine alone or with docetaxel for patients with metastatic breast cancer (2008) (5)
TAG-72 as a Tumor Marker (1992) (5)
Radioimmunotherapy of colon cancer with an improved humanized monoclonal antibody design (2002) (5)
Construction of phosphorylatable monoclonal antibody CC49 with a casein kinase II recognition site. (1998) (5)
Reactivities of an anti-CEA peptide monoclonal antibody (1992) (5)
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing (2021) (5)
The use of molecular hybridization to track the mode of transmission and distribution of murine mammary tumor viruses: a model for etiologic studies of human breast cancer. (1978) (5)
Differential host ranges for in vitro infectivity of mouse mammary tumour viruses. (1980) (5)
The use of monoclonal antibody B72.3 in the management of gynecologic malignancies. (1988) (5)
Abstract 594: Dual targeting of TGFb and PD-L1 promotes potent anti-tumor efficacy in multiple murine models of solid carcinomas (2017) (5)
In vivo gene inoculation of a recombinant single-chain antitumor antibody induces anti-immunoglobulin response. (1997) (5)
Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses (2015) (5)
Carcinoembryonic Antigen as a Vaccine Target (2001) (5)
PSA-ENCODING ADENOVIRUS INDUCES POTENT ANTITUMOR IMMUNITY IN A MOUSE PROSTATE TUMOR MODEL (1999) (5)
Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I (1994) (5)
A Phase 2 Randomized Trial of Docetaxel Alone or in Combination with Therapeutic Cancer Vaccine, CEA-, MUC-1-Tricom (2012) (5)
Loss of a c-Hras-1 AlÃ-eleand Aggressive Human Primary Breast Carcinomas 1 (2006) (5)
Immunotherapy for biochemically recurrent prostate cancer. (2018) (5)
Cancer vaccine development. (1998) (5)
Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets (2014) (5)
Discussion: Immunological Therapeutics in Ovarian Cancer (2003) (5)
Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells (2005) (4)
Cancer vaccines and immunotherapy: Vaccines for colon cancer (2000) (4)
A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned. (2010) (4)
Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic (2021) (4)
A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA. (2011) (4)
Abstract 3245: IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity of murine breast and colon carcinomas (2016) (4)
Chapter 11 – Type B and Type D Retroviruses (1980) (4)
616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1) (2020) (4)
Intraprostatic vaccine administration in patients with locally recurrent prostate cancer. (2011) (4)
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies (2022) (4)
Abstract 4901: Short-course enzalutamide reveals immune activating properties in patients with biochemically recurrent prostate cancer (2016) (4)
Monoclonal Antibody Gene Transfer: Implications for Tumor‐Specific Cell‐Mediated Cytotoxicity a (1994) (4)
Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy (2014) (4)
A pilot study of a PANVAC-V and PANVAC-F in patients (pts) with metastatic carcinoma. (2006) (4)
Construction of phosphorylatable chimeric monoclonal antibody CC49 with a tyrosine srC kinase recognition site. (1998) (4)
Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer (2012) (4)
A phase II study of a yeast-based therapeutic cancer vaccine, GI-6207, targeting CEA in patients with minimally symptomatic, metastatic medullary thyroid cancer. (2013) (4)
16 – Colon Carcinoma Cell Population as Defined by Monoclonal Antibodies (1990) (4)
Phase I S tudy i n C ancer P atients o f a R eplication-Defe ctive Avipox R ecombinant V accine T hat E xpresses H uman Carcinoembryonic A ntigen (1999) (4)
Safety profile of recombinant poxviral TRICOM vaccines. (2013) (3)
Indirect leukocyte migration inhibition in breast cancer and benign breast disease patients by mouse mammary tumor virus grown in feline kidney cells. (1984) (3)
Costimulatory molecules in vaccine design. (2000) (3)
Sequences related to the RNA tumor viruses in the RNA and DNA of human leukemias and lymphomas. (1975) (3)
Systemic radioimmunotherapy in synergy with vaccine renders antitumor effects in a preclinical model (2006) (3)
7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) (2009) (3)
Williamsburg Conference on Biological and Immunological Treatments for Cancer, 1992. (1993) (3)
Correlation between the detection of specific mouse mammary tumor proviral sequences and the presence of pulmonary metastases in mice bearing spontaneous mammary tumors. (1980) (3)
Breast cancer: molecular basis for a viral etiology. (1974) (3)
The use of standard and relaxed hybridization conditions to detect two classes of sequences related to type-D retroviruses in the DNAs of primates. (1978) (3)
Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer. (2011) (3)
Abstract 4790: Docetaxel modulates phenotype of human carcinoma cells, including drug-resistant tumor cells, resulting in enhanced killing by CTLs (2010) (3)
Construction of phosphorylatable monoclonal antibody to a tumor-associated antigen. (1996) (3)
Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301) (2014) (3)
Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial). (2018) (3)
Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa (2021) (3)
Construction of phosphorylatable chimeric monoclonal antibody CC49 with a casein kinase I recognition site. (1999) (3)
Vaccine strategies for the therapy of ovarian cancer (2003) (3)
And their use (2002) (3)
Use of molecular hybridization to detect type D retrovirus markers in rhesus placentas and other tissues. (1979) (3)
Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model (2014) (3)
A monoclonal antibody (B72.3) to adenocarcinoma of the colon and related tumors. (1989) (3)
Abstract OT3-04-01: Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study (2019) (3)
GENERATION OF SPECIFIC ANTI-HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) CYTOTOXIC T LYMPHOCYTES FROM A COLON CARCINOMA PATIENT IMMUNIZED WITH RECOMBINANT VACCINIA-CEA (rVCEA) VACCINE BY STIMULATION WITH A CEA SYNTHETIC PEPTIDE (CAP-2) IN VITRO (1996) (3)
Exercise, alone and in combination with an anti-CEA vaccine, reduces pancreatic tumor cell growth and enhances survival in mice. (2008) (3)
Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab′ (1993) (3)
The National Institutes of Health Experience with Radiolabeled Monoclonal Antibodies: Lymphoma, Melanoma, and Colon Cancer (1988) (3)
Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies. (1991) (3)
Evidence for an RNA tumor viruses in human milk. (1975) (3)
The MUC1-C oncoprotein as a target in hematologic malignancies (2010) (3)
MP16-14 CLINICAL OUTCOMES OF A RANDOMIZED, PROSPECTIVE, PHASE II STUDY TO DETERMINE THE EFFICACY OF BACILLUS CALMETTE-GUERIN (BCG) GIVEN IN COMBINATION WITH PANVAC VERSUS BCG GIVEN ALONE IN ADULTS WITH HIGH GRADE BCG-REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCER (2021) (3)
Improved experimental radioimmunotherapy of colon xenografts by combining 131I-CC49 and interferon-gamma. (1994) (3)
Combination Therapies for HPV-Associated Malignancies (2020) (2)
GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR PROSTATE SPECIFIC ANTIGEN EPITOPES FROM HLA-A2 and HLA-A3 MALE DONORS (1996) (2)
Anti-tumor efficacy and immune responses induced by a novel therapeutic HPV-specific gorilla adenovirus off-the-shelf immunotherapeutic (PRGN-2009) (2020) (2)
Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy (2020) (2)
Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy. (2018) (2)
Visna virus: a "slow" neurotropic agent with tumor virus properties. (1971) (2)
Generation of Monoclonal Antibodies Reactive with Human Colon Carcinomas (1984) (2)
Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer. (2022) (2)
The molecular genetics of human cancer and its etiologic implications. (1975) (2)
The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors (2014) (2)
A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer. (2012) (2)
RECOMBINANT VIRAL AND BACTERIAL VACCINES (2007) (2)
Prospect: A randomized, double-blind, phase III efficacy trial of PROSTVAC. (2012) (2)
Monoclonal antibody RAP-5 and ras p21 expression. (1988) (2)
Abstract OT2-03-04: A trial of induction Talazoparib followed by a combination of Talazoparib and Avelumab in advanced breast cancer: The TALAVE study (2020) (2)
Regulation of human tumor antigen expression by biological response modifiers (BRMs). (1991) (2)
681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc) (2020) (2)
456 Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy (2020) (2)
The impact of leukapheresis on immune-cell number and function in patients with advanced cancer (2015) (2)
Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72 (1993) (2)
Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer (2004) (2)
Abstract 1480: Systemic immunotherapeutic efficacy of an immunocytokine, NHS-muIL12, in a superficial murine orthotopic bladder cancer model (2016) (2)
Characterization of a retrovirus isolated from normal mink cells co-cultivated with a dog mammary tumour. (1979) (2)
Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation. (2017) (2)
SO-28 A randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer (2020) (2)
Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity (2022) (2)
Antigenic Heterogeneity of Human Mammary Carcinoma Cells Defined by Monoclonal Antibodies (1984) (2)
A STUDY OF RECOMBINANT ALVAC-CEA IN PATIENTS WITH ADVANCED CEA-BEARING CANCERS (1996) (2)
Concepts in the delivery of monoclonal antibodies in the targeting of human carcinomas (1988) (2)
Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells (2005) (2)
Recombinant cancer vaccines and new vaccine targets (2013) (2)
A phase I trial of a recombinant CEA yeast-based vaccine targeting CEA-expressing cancers. (2012) (2)
Contrasting autoimmune and treatment effects reveals baseline set points of immune toxicity following checkpoint inhibitor treatment (2022) (2)
A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-β pathways, in patients with metastatic or locally advanced solid tumors (2016) (2)
A randomized phase II clinical trial of enzalutamide in combination with the therapeutic cancer vaccine, PSA tricom, in metastatic, castration resistant prostate cancer. (2013) (2)
Use of Samarium-153 (Quadramet) to modulate phenotype and enhance killing of tumor cells (2006) (2)
Enhanced Expression of Surface Tumor Associated Antigens on Human Breast and Colon Tumor Cells by Recombinant Human Interferon (1985) (2)
Chapter 20 – Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned (2013) (2)
Insights on Peptide Vaccines in Cancer Immunotherapy (2015) (2)
Droplet-Digital PCR Provides a Rapid, Accurate and Cost-Effective Method for Identification of Biomarker FcÃÂ³RIIIa-F158V Genotypes (2017) (2)
Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor (2015) (2)
The use of a panel of monoclonal antibodies in ultrastructurally characterized small cell carcinomas of the lung. (1988) (2)
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies (2012) (2)
Retroviral-related genes, proto-oncogenes, and breast cancer. (1989) (2)
The relevance of RNA tumor viruses to human cancer. (1973) (2)
Calculation of an immunoscore based on extensive flow cytometry analysis of PBMCs from metastatic breast cancer patients treated with docetaxel alone or in combination with vaccine. (2013) (2)
The search for RNA tumor viruses in human cancer. (1975) (2)
Safety profile of poxviral vaccines: NCI experience. (2013) (2)
Monoclonal antibodies in the management of carcinoma patients (1991) (2)
Abstract OT1-08-01: A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT) (2020) (2)
Abstract 1586: Recovery and characterization of circulating tumor cells (CTCs) in cryopreserved metastatic castrate-resistant prostate cancer (mCRPC) patient samples (2015) (1)
Measurements of human anti murine antibodies in patients who received radiolabeled monoclonal antibodies (1986) (1)
Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems (2019) (1)
The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study. (2022) (1)
PRODUCTION OF CD4+ AND CD8+ T CELL LINES FROM PATIENTS VACCINATED WITH MUTATED RAS PEPTIDES (1996) (1)
Abstract 5012: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates (2014) (1)
TRICOM Poxviral-Based Vaccines for the Treatment of Cancer (2014) (1)
The IDO inhibitor INCB024360 to enhance dendritic cell immunogenicity and anti-tumor immunity in vitro. (2015) (1)
Vaccinationwith a Recombinant Saccharomyces cerevisiae Expressing aTumorAntigen Breaks ImmuneTolerance and ElicitsTherapeutic Antitumor Responses (2008) (1)
Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells (2013) (1)
The Organization of Mouse Mammary Tumor Virus Related Sequences in Human Cellular DNA (1985) (1)
Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies. (2022) (1)
Viruses and Mammary Carcinoma (1978) (1)
Diet-induced obesity impairs both innate and adaptive immune responses. (2006) (1)
Chemotherapy can Enhance the Therapeutic Potential of Vaccine-mediated Immunotherapy (2009) (1)
Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer. (2012) (1)
Hereditary breast cancer: Search for biomarkers (1987) (1)
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies (2012) (1)
A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies. (2021) (1)
Immunological therapeutics in ovarian cancer (2003) (1)
Safety profile of therapeutic pox virus-based vaccines for cancer. (2004) (1)
Chemical carcinogen-mouse mammary tumor virus interactions in cell transformation (2007) (1)
Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors (2017) (1)
Translational ResearchWorking Group Developmental Pathway for Immune ResponseModifiers (2008) (1)
Radioimmunotherapy for metastatic prostate cancer using a high affinity antibody (1993) (1)
Diet-induced obesity promotes pancreatic tumor growth in mice. (2006) (1)
GENERATION, CHARACTERIZATION, AND UTILIZATION OF MONOCLONAL ANTIBODIES REACTIVE WITH HUMAN MAMMARY CARCINOMA ASSOCIATED ANTIGENS (1982) (1)
PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients (2014) (1)
Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells (2015) (1)
Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT) (2013) (1)
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status (2022) (1)
Identification of Novel Human CTL Epitopes and TheirAgonist Epitopes ofMesothelin (2005) (1)
Evaluation of the anti-tumour efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent (2019) (1)
Combination of a therapeutic cancer vaccine and immune checkpoint inhibitors in prostate cancer. (2018) (1)
483 Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers (2021) (1)
Phase I trial of CV301 in combination with anti-PD-1 therapy in non-squamous NSCLC (2019) (1)
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis (2021) (1)
160 Recombinant Vector-Based Vaccines for Cancer Therapy (2011) (1)
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors. (2023) (1)
Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability. (2018) (1)
A New Class of Human Endogenous Retroviral Genes (1985) (1)
Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer. (2022) (1)
antigen-presenting cells avipox-vector infection: an alternative source of efficient Human B cells that hyperexpress a triad of costimulatory molecules via (2013) (1)
Phase I Study of Immunizationwith Dendritic Cells Modifiedwith Fowlpox Encoding Carcinoembryonic Antigen and CostimulatoryMolecules (2005) (1)
Safety profile of therapeutic pox virus-based vaccines for cancer (2004) (1)
The Importance of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19 (2020) (1)
Vaccination of CEA-transgenic mice with a recombinant Saccharomyces cerevisiae-CEA vaccine breaks immune tolerance and elicits therapeutic antitumor responses (2007) (1)
Pox Viral Vaccines (2004) (1)
Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors. (2022) (1)
SPECIFIC ACTIVE IMMUNOTHERAPY USING A RECOMBINANT VACCINIA VIRUS EXPRESSING HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) (1992) (1)
IMPROVED IMMUNOTHERAPEUTIC EFFICACY OF AN ANTI-CARCINOMA MONOCLONAL ANTIBODY (CC49) WHEN GIVEN IN COMBINATION WITH IFN-γ (1993) (1)
A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC). (2021) (1)
Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine (2013) (1)
Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact. (2016) (1)
Difference in the biodistribution of indium and yttrium labelled monoclonal antibodies (1989) (1)
A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance. (2022) (1)
Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target (2013) (1)
Non-HLA antigens in breast cancer. (1983) (1)
Impact of standard chemotherapy on peripheral blood immune cell subsets in metastatic colorectal cancer. (2015) (1)
2125 Enhanced intraperitoneal radioimmunotherapy with adjuvant Interferon and Taxol (1997) (1)
Abstract 1740: Epigenetic reprogramming of the tumor microenvironment by entinostat increases tumor sensitivity to multivalent immunotherapy combinations with an IL-15 superagonist plus vaccine or immune checkpoint blockade (2018) (1)
Diversity ofMammaryTumorViral GenesWithin theGenus Mus,theSpecies Musmusculus, andtheStrain C3H (1979) (0)
909 Overcoming resistance to NK-mediated lysis in enzalutamide-resistant prostate cancer cells (2022) (0)
Abstract B62: A novel combination HER2, brachyury, and MUC1 adenovirus based vaccines for a multitargeted immunotherapy approach to treat breast cancer (2016) (0)
Analysis of the ability of recombinant yeast (Saccharomyces cerevisiae)vector encoding carcinoembrionic antigen (CEA) to infect dendritic cells and activate antigen-specific T-cell responses (2007) (0)
Spatial analysis of tumor immune microenvironment (TIME) in patients treated with Bintrafusp alfa. (2020) (0)
An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC (2022) (0)
Abstract B64: A high-throughput screen identifies fulvestrant as an enhancer of immune-mediated cytotoxicity of mesenchymal-like lung cancer cells (2017) (0)
ANALYSES OF DIFFERENT GENETICALLY ENGINEERED IMMUNOGLOBULIN FORMS FOR TUMOR TARGETING AND THERAPY (1994) (0)
605 NHS-IL12 plus Entinostat combination effectively targets anti-PD-1/PD-L1 checkpoint resistant murine tumors harboring MHC Class I and antigen processing machinery deficiency (2021) (0)
Suppl 1 to Vol. 52: The Albert B. Sabin Vaccine Institute 4th Annual Colloquium on Cancer Vaccines and Immunotherapy, 6-10 March 2002, Walker's Cay, Abaco, Bahamas (2003) (0)
Correction (2019) (0)
PSA Oligoepitope Peptide Prostate-Specific Antigen (PSA) Employing a Lymphocyte Lines Directed Against Generation of Human Cytolytic T (1998) (0)
HUMAN HLA-A2-RESTRICTED, CD8+ CYTOTOXIC T-CELLS RECOGNIZE AND LYSE TUMOR CELLS ENDOGENOUSLY EXPRESSING A K-RAS POINT MUTATION AT CODON 12 (1996) (0)
Abstract 498: A combination trial of vaccine plus ipilimumab in patients with metastatic castration-resistant prostate cancer: immune correlates. (2013) (0)
EXTH-63. EFFICIENT ADCC-MEDIATED KILLING OF MALIGNANT MENINGIOMA CELLS USING AVELUMAB AND AN ENGINEERED HIGH AVIDITY NATURAL KILLER CELL LINE, haNK (2018) (0)
A PHASE I TRIAL OF VACCINE THERAPY WITH TUMOR SPECIFIC MUTATED RAS PEPTIDES ADMINISTERED SUBCUTANEOUSLY IN CANCER PATIENTS (1995) (0)
Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report (2021) (0)
695 Immune correlates associated with clinical benefit in patients with immune checkpoint refractory HPV-associated malignancies treated with triple combination immunotherapy (2022) (0)
IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model (2015) (0)
C-103 Multimodal approach to cancer immunotherapy (2019) (0)
Antibody Variant by Retention of SDRs Only Development of a Minimally Immunogenic Specificity-Determining Residues (SDRs) and Antibody: Identification of Structural Correlates of an Anticarcinoma (2000) (0)
INDUCTION OF CD8+ CYTOTOXIC T-LYMPHOCYTES AGAINST THE POINT-MUTATED K-RAS ONCOGENE (1995) (0)
Combination Immunotherapy Lymphocytes: A Rationale for Its Use in Lymphocytes while Preserving Effector T Decreases Human T Regulatory Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), (2014) (0)
Oligoepitop-peptide of prostate-specific antigen (1997) (0)
The T-box transcription factor Brachyury controls tumor cell migration and invasion (2008) (0)
Abstract B04: Multimodal cancer immunotherapy combining IL-8 inhibition, adenovirus vaccine, IL-15 super agonist, and anti-PD-L1/TGFβRII agent reduces mesenchymalization and enhances anti-tumor efficacy (2020) (0)
Abstract P3-05-04: An IL-15 superagonist enhances antibody-dependent cell-mediated cytotoxicity against breast cancer cells regardless of FCGR3A (CD16) genotype and rescues NK cell from TGF-β1-induced immunosuppression (2018) (0)
Vaccine therapy with tumor-specific mutated ras peptides and IL-2, GM-CSF, or both in adult patients with solid tumors. (2012) (0)
CORRELATION BETWEEN THE DEVELOPMENT OF MURINE MAMMARY CANCER AND THE SEGREGATION OF ENDOGENOUS GENES (1980) (0)
Cytokine-Based Modalities to Enhance Monoclonal-Antibody-Mediated Tumor Cell Killing (2018) (0)
The Requirement ofMultimodalTherapy ( Vaccine , LocalTumor Radiation , and Reduction of Suppressor Cells ) to Eliminate EstablishedTumors (2005) (0)
Multiple Costimulatory Modalities Enhance (2005) (0)
Targets for Vaccine Therapy (2003) (0)
Altering the Balance of Signals from APC Selective Induction of High Avidity CTL by (2003) (0)
Detection of Type-Specific Antigenic Determinants of Murine Mammary Tumor Viruses with Cell-Mediated Immune Assays (1982) (0)
Docetaxel Alone or in CombinationWith a Therapeutic Cancer Vaccine ( PANVAC ) in PatientsWithMetastatic Breast Cancer A Randomized Clinical Trial (2015) (0)
Use of Monoclonal Antibodies to Define the Diversity of Mammary Tumor Viral Gene Products in Virions and Mammary Tumors of the Genus Mus 1 (2006) (0)
Exercise Improves Innate and Adaptive Immune Responses in Obese Mice: 1400 (2010) (0)
As vectors to treat and prevent pancreatic cancer (2004) (0)
Comparative Studies on the Molecular Basis for a Viral Involvement in Murine and Human Mammary Adenocarcinoma (1975) (0)
Abstract 3979: In vitro analysis of pan-BCL-2 inhibitor GX15-070 (obatoclax) on human lymphocytes for the feasibility of combination immunotherapy. (2013) (0)
The marriage of cancer vaccines and antiangiogenesis (2005) (0)
SYNERGISTIC IN VIVO EFFECTS OF IL-6 AND IFNGAMMA ON CEA AND HLA CLASS I SURFACE EXPRESSION IN COLORECTAL TUMOR CELLS (1995) (0)
Chapter 3 RNA Tumor Viruses and Breast Cancer (1976) (0)
Abstract 5379: Combination treatment with Bevacizumab, Lenalidomide, Docetaxel and Prednisone (ART-P) does not impact the immune response in patients with metastatic castration-resistant prostate cancer (2012) (0)
Importance of dose scheduling of denileukin diftitox/vaccine combination therapy to reduce T regs and to enhance immune responses (2007) (0)
Abstract 1232: Immunomodulatory effects of a tyrosine kinase inhibitor and vascular remodeling properties of a cancer vaccine potentiate combinatorial immunotherapy. (2013) (0)
Immunogenic peptides and use procedures for (2007) (0)
Potential Clinical Application of a Monoclonal Antibody to a Tumor Associated Glycoprotein (TAG-72) (1985) (0)
Vaccines containing multiple comstimulatory molecules promote the proliferation and activation of human antigen specific memory CD8 T cells. (2006) (0)
B-105 Emerging Concepts in Cancer Immunotherapy (2017) (0)
582 Immune correlates from QuEST1 in men with castration-resistant prostate cancer (2021) (0)
Abstract 2405: Treatment of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces number and function of regulatory T cells (Tregs) and enhances the ratio of antigen-specific effectors to Tregs (2010) (0)
Therapeutic efficacy of a radiolabeled anti carcinoembryonic antigen cea monoclonal antibody (1992) (0)
PHASE II TRIAL OF 131*** CC49 PLUS ALPHA INTERFERON (***FN α) IN REFRACTORY METASTATIC BREAST CANCER (1994) (0)
Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors. (2019) (0)
EVIDENCE THAT RECOMBINANT INTERFERONS CAN ENHANCE THE SENSITIVITY OF THE DETECTION OF SERUM TAG-72 AND CEA IN PATIENTS DIAGNOSED WITH ADENOCARCINOMA (1992) (0)
Commentary (Schlom et al): Novel Vaccines for the Treatment of Gastrointestinal Cancers (2005) (0)
570 Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization (2021) (0)
Issues in Cancer Vaccine Development (2003) (0)
Combining a Recombinant CancerVaccinewith Standard Definitive Radiotherapy in Patientswith Localized Prostate Cancer (2005) (0)
Abstract 5404: Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer (2012) (0)
Abstract 758: Cancer vaccine immunotherapy employing Saccharomyces cerevisiae (yeast) as a vector can modulate the balance between CD4+ T cells and regulatory T cells (Tregs) and enhance the specific antitumor immune response (2011) (0)
T cell-mediated suppression of angiogenesis results in tumor protective immunity. Commentary (2005) (0)
T-Cell Activation A Triad of Costimulatory Molecules Synergize to Amplify Updated (1999) (0)
Patient-specific vectors for the treatment and prevention of pancreatic cancer (2004) (0)
Type-specific and group-specific antigenic determinants on the major external and internal proteins of mouse mammary tumor viruses (mmtvs). Abstr. (1978) (0)
P-133 Clinical responses in pancreaticobiliary cancer patients who received bintrafusp alfa (BA) or BA plus CXCR1/2 inhibitor (SX-682) plus CEA/MUC1-targted vaccine (CV301) (2022) (0)
An analysis of sodium 18f-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC). (2016) (0)
RNA tumor viruses and breast cancer. (1976) (0)
A phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC) (2019) (0)
Immunohistochemical analyses of tumor-associated glycoprotein in gastric and breast carcinomas (1989) (0)
6 Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa (2021) (0)
A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus VaccineAlone in Metastatic Androgen-Independent Prostate Cancer (2006) (0)
Abstract 1403: Correlations between overall survival and patient regulatory T-cell levels at initiation of Folfiri therapy in colorectal cancer (2016) (0)
540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors (2021) (0)
1337 Preclinical evaluation of STAR0602, a novel, first-in-class anti-TCR Vb targeted bispecific antibody with potent anti-tumor activity for PD-1 refractory solid tumors (2022) (0)
Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL (2015) (0)
A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer. (2021) (0)
Erratum: Multiple costimulatory modalities enhance CTL avidity (Journal of Immunology (2005) 174 (5994-6004)) (2005) (0)
Differential Expression of DF3 Antigen between Papillary Carcinomas and Benign Papillary Lesions of the Breast (1989) (0)
Development of a CEA peptide-specific T cell line that exhibits anti-tumor properties in a CEA-transgenic experimental model (1999) (0)
Abstract 2546: Analysis of immune cell subsets in a multidrug therapeutic regimen for patients with metastatic castration-resistant prostate cancer (2014) (0)
Abstract 4032: Modulation of tumor PD-L1 expression by epithelial-mesenchymal phenotypic plasticity (2016) (0)
Abstract C53: Overexpression of Brachyury in human carcinoma cells drives the acquisition of resistance to anticancer therapeutics (2011) (0)
Abstract PL03-02: Current status of recombinant pox-viral vaccines (2012) (0)
2105 Phase 1 trial of intraperitoneal radioimmunotherapy for ovarian cancer (1996) (0)
Abstract PR20: A novel combination immunotherapy with a vaccine targeting tumor neoepitopes that mediates immune cascade in murine tumor models (2020) (0)
Measurement of the effect of interferons on the proliferative capacity and cloning efficiency of normal and leukemic human myeloid progenitor cells in culture. (1986) (0)
[Recent advances in tumor markers]. (1988) (0)
Novel vaccines for the treatment of gastrointestinal cancers: Commentary (2005) (0)
D-104 Harnessing the potential of HDAC inhibitors for immunotherapy combinations (2019) (0)
CYTOTOXIC ACTIVITY BY PEPTIDE-INDUCED CD4+ T-LYMPHOCYTES AGAINST TUMOR CELLS EXPRESSING POINT-MUTATED Ki-RAS (1994) (0)
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells (2014) (0)
PS2:28 Autoantibody profiling in prostvac and ipilimumab treated prostate cancer patients reveals potential biomarkers of immune-related adverse events (2018) (0)
Abstract 1406: Analysis of immune responses as a consequence of androgen deprivation therapy in patients with biochemical progression of prostate cancer (2016) (0)
85. Molecular and biological characteristics of a potentially novel human gastric tumor antigen (1992) (0)
Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance. (2022) (0)
Maintain High Avidity Memory CTL Vaccines with Enhanced Costimulation (2005) (0)
Basic Principles and Applications of Monoclonal Antibodies in the Management of Carcinomas: The Richard and Hinda Rosenthal Foundation Award Lecture1 (2006) (0)
In-situ diversification of immunity following vaccination targeting tumor neoepitopes; an integral component of combinatorial immunotherapy (2019) (0)
Abstract A64: Brachyury-mediated epithelial-mesenchymal transition of human carcinoma cells is associated with an increased resistance to immune-mediated attack (2011) (0)
Abstract A16: Natural killer cell therapy efficacy is enhanced through inhibition of myeloid-derived suppressor cell trafficking (2020) (0)
Q 1 2 Immune Q 2 Impact Induced by PROSTVAC ( PSA-TRICOM ) , Q 3 3 a Therapeutic Vaccine for Prostate Cancer 4 5 (2013) (0)
Abstract 5085: Blockade of tumor derived CSF1 promotes an immune-permissive tumor microenvironment (2023) (0)
encoding for multiple costimulatory molecules (CLL): enhanced immunogenicity of CLL cells via infection with vectors Potential approach to immunotherapy of chronic lymphocytic leukemia (2013) (0)
Monoclonal antibodies, benign breast disease, and breast cancer (2005) (0)
445 Blockade of the inhibitory collagen receptor LAIR-1 with NC410, a LAIR2-Fc fusion protein, enhances anti-tumor activity of the bifunctional fusion protein bintrafusp alfa (2020) (0)
Phase I Trial of a PSA based vaccine and ipilimumab in patients (pts) with metastatic castrate resistant prostate cancer (CRPC) (2007) (0)
Abstract 2544: Identification of immune signatures predicting for clinical outcome measured by flow-cytometry and immunogenetic analysis of PBMCs from breast cancer patients treated with docetaxel alone or docetaxel plus vaccine (2014) (0)
THU0043 Autoantibody profiling in prostvac and ipilimumab treated prostate cancer patients reveals potential biomarkers of immune-related adverse events (2018) (0)
Phase 1 trial of CV301 in combination with anti‐PD‐1 therapy in nonsquamous non‐small cell lung cancer (2022) (0)
Abstract 611: Reversion of mesenchymal features in NSCLC cells using M7824, a first-in-class bi-functional immunotherapeutic agent targeting PD-L1 and TGFβ1 (TGFβ TRAP) (2017) (0)
The use of B72.3 second generation (CC) monoclonal antibody for the radioimmunolocalization of human carcinoma xenografts (1989) (0)
Generation of immune responses with the prostate specific antigen (SPA) (1996) (0)
Introduction: Therapeutic cancer vaccines. (2012) (0)
Generating immune responses to specific antigen (PSA) responses. (1996) (0)
Abstract 5378: Phase I trial of EUS-guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer (2012) (0)
T Cell Interaction Involvement of CD80 Acquisition in T Cell to Early Stages of Activation: Functional Acquisition of CD80 by Human T Cells at (2002) (0)
Abstract P034: Tumor-targeted interleukin-12 and Entinostat combination therapy improves cancer survival by reprogramming the tumor immune cell landscape (2022) (0)
970 PROSPECT: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 EFFICACY TRIAL OF PROSTVAC-VF IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2013) (0)
complex, is a check-point of memory T cell homeostasis Acquisition of Antigen Presentasomes (APS), an MHC/costimulatory (2013) (0)
Abstract #LB-161: Gemcitabine preconditioning improves antigen-specific immune and antitumor responses to poxvirus vaccines. (2009) (0)
Chapter 11 Human Breast Cancer Markers Defined by Monoclonal Antibodies (1985) (0)
Immunoadjuvant Lymph Nodes with Antigen-presenting Cells and Acts as an by Recombinant Avian Poxviruses Enriches the Regional Granulocyte / Macrophage-Colony Stimulating Factor Produced Updated (2000) (0)
Abstract B29: The importance of epitope spreading in the generation of effective antitumor immunity in mice treated with combination immunotherapy (2020) (0)
Problem Areas in Immunotherapy (2003) (0)
Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers. (2023) (0)
Monoclonal antibodies and immobilized antibodies (1987) (0)
Mono clonal antibodies define type group and interspecies antigenic determinants of rodent type b retroviruses associated with mammary carcinomas (1980) (0)
Ultrastructural immunolocalization of tumor-associated glycoprotein (TAG-72) in human gastric and mammary carcinomas (1989) (0)
Abstract 6100: Chemotherapy reduces TGF-beta signaling triggered by blockade of the PD-1/PD-L1 axis (2022) (0)
TGF-β inhibits central memory cell differentiation in CD8 T-cells (52.14) (2012) (0)
Novel Endogenous Retroviral Genomes in Human Genomic DNA (1986) (0)
Biology and Immunology of Human Carcinoma Cell Populations (1984) (0)
Abstract CN04-01: Targeting the epithelial-mesenchymal transition via brachyury-based cancer vaccines (2015) (0)
Inhibition of TGF-b1 Signaling Promotes Central Memory T Cell Differentiation (2013) (0)
Immunologic heterogeneity of mammary tumor cells defined by monoclonal antibodies to tumor-associated antigens (TAAs) (1982) (0)
Development of agonist epitopes of the human papillomavirus (2017) (0)
Immunotherapy utilizing the combined use of NK and ADCC mediating agents with PARP inhibition. (2018) (0)
THE NATIONAL INSTITUTES OF HEALTH EXPERIENCE WITH RADIO- LABELED MONOCLONAL ANTIBODIES: LYMPHOMA, MELANOMA, AND COLON CANCER (0)
Cancer Immunology, Immunotherapeutics, and Vaccine Approaches (2010) (0)
Generation of human cytotoxic T cells, genes of carcinomas and their applications (1996) (0)
766 Phase I/II evaluation of the combination of entinostat, M9241 and bintrafusp alfa in patients with advanced HPV related malignancies (2022) (0)
Abstract B43: Identification of prognostic markers for prostate cancer by serum profiling with a carbohydrate antigen microarray (2010) (0)
Adjunct to Multiple Serum Markers Analyses and Demonstration of Its Potential Importance as an for Carcinoembryonic Antigen Messenger RNA : Longitudinal by Nested Reverse Transcription-Polymerase Chain Reaction Detection of Blood-borne Cells in Colorectal Cancer Patients (2001) (0)
Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival (2013) (0)
Exploiting tumor necrosis with novel immunotherapies (2020) (0)
Abstract B82: Identification of tumor neoantigens for combination therapy in murine tumor models (2018) (0)
Humanized col-1 antibody with substituted residues at the skeleton, and their application (2005) (0)
Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation. (2004) (0)
Combination chemoimmunotherapy in a pancreatic cancer model. (2006) (0)
DEVELOPMENT OF A RECOMBINANT VACCINIA-CARCINOEMBRYONIC ANTIGEN (CEA) VACCINE FOR IMMUNOTHERAPY OF HUMAN CARCINOMA (1993) (0)
727 Resistance to enzalutamide and abiraterone drives tumor phenotypic plasticity and resistance to immune-mediated cytotoxicity (2021) (0)
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa (2020) (0)
Useof MolecularHybridizationto Detect Type D RetrovirusMarkers in RhesusPlacentasand Other Tissues 1 (0)
Recombinant TRICOM-based Therapeutic Cancer Vaccines (2013) (0)
Abstract CN07-03: Brachyury and the interleukin-8 axis in tumor progression (2018) (0)
Table 60-4, Immunostimulants for Cancer Immunotherapy (2003) (0)
344 Monoclonal antibodies against human mammary tumor associated antigens (1983) (0)
Low-level transforming activity of an activated Ras gene under the control of a vaccinia virus p40 promoter is abrogated by truncation of the Ras cDNA. (1999) (0)
CHARACTERIZATION OF RECOMBINANT CEA PRODUCED IN A BACULOVIRUS EXPRESSION SYSTEM (1993) (0)
Karcinoembryonale antigen -expressing recombinant virus and methods of their application (1992) (0)
Abstract A43: Exploiting off-target effects of estrogen receptor-targeting drugs to sensitize breast cancer to immune killing (2020) (0)
Proceedings: Genetics and the cancer cell: molecular evidence for a viral etiology of human cancer. (1972) (0)
Molecules in Human Dendritic Cells Vector-mediated Hyperexpression of a Triad of Costimulatory Enhanced Activation of Human T Cells via Avipox Updated (2001) (0)
Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM (2014) (0)
A composition comprising an antigen-expressing recombinant virus and an immunostimulatory molecule expressing recombinant virus (1995) (0)
Multiple costimulatory modalities enhance CTL avidity (2005) (0)
Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer. (2023) (0)
Abstract 5524: Generation of cellular immune responses to MUC1-C to target the portion of MUC1 that is most biologically relevant to the transformation process (2011) (0)
153. Improved antinimor efficacy of a radiolabeled monoclonal antibody when combined with interferon-gamma (1992) (0)
Biodistribution of monoclonal antibody in patients with metastatic colorectal cancer: In vivo comparison of 111In vs 125I-B72.3 IgG (1989) (0)
C-101 Therapeutic Cancer Vaccines—Fundamental Insights (2014) (0)
Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody (2014) (0)
Monoclonal antibodies of the second generation having binding specificity for TAG-72 and human carcinomas, and methods for their application (1988) (0)
Abstract 3644: Combination of OX40L fusion protein with an anti-tumor vaccine reduces lung metastasis and prolongs survival in a murine model of metastatic triple negative breast cancer (2017) (0)
Abstract 1536: A novel immunocytokine generates a CD8+ T cell-mediated anti-tumor response in vivo (2012) (0)
Vaccine Therapy and Integration with Other Modalities (2013) (0)
Immunity Contribute to T Cell Activation and Tumor Soluble CD 27-Pool in Humans (2013) (0)
TGF-{beta} inhibits central memory cell differentiation in CD8 T-cells (2012) (0)
ROLE OF INTERLEUKIN-2 IN THE ANTITUMOR ACTIVITY OF A RECOMBINANT CARCINOEMBRYONIC ANTIGEN-VACCINIA VIRUS (rV-CEA) VACCINE (1994) (0)
Report of the second annual walker's cay colloqium on cancer vaccines and immunotherapy, March 8-11, 2000. (2000) (0)
Abstract C241: Phase I trial of EUS-guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer. (2011) (0)
The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance (2014) (0)
IMPROVED TUMOR TARGETING OF A GENETICALLY ENGINEERED SINGLE-CHAIN Fv (sFv) OF THE PANCARCINOMA MONOCLONAL ANTIBODY (MAb) CC49 WHEN GIVEN IN COMBINATION WITH INTERFERON-GAMMA (IFY-γ) (1994) (0)
710 Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist) (2021) (0)
ARandomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus VaccineAlone inMetastatic Androgen-Independent Prostate Cancer (2006) (0)
Monoclonal Antibodies in the Management of Breast Cancer (1986) (0)
Regulatory T Cells Functionality of Tumor-Infiltrating Signaling Results in Compromised Tumor-Induced Impairment of TCR (2008) (0)
Monoclonal Antibodies Generated to a Synthetic Peptide Define Ras Gene Expression at the Single Cell Level in Human Colon and Mammary Carcinomas (1985) (0)
Abstract PD9-02: Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study (2022) (0)
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein (2013) (0)
T-Cell Costimulation (2003) (0)
Types of Vaccines (2003) (0)
Modification of B-CLL Cells Via Infection with a Replication-Defective MVA Virus Encoding Three Costimulatory Molecules: A Potential Approach to Tumor Cell Immunotherapy of B-CLL. (2004) (0)
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis (2021) (0)
Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer. (2014) (0)
Evaluation of poxviruses targeting the tumor microenvironment for cancer therapy. (2010) (0)
Analysis of PSA-Specific T-Cell Responses of Prostate Cancer Patients Given a PSA-Based Vaccine on a Clinical Trial (2003) (0)
SYNERGISTIC ACTION OF INTERFERON-GAMMA (IFN-γ) AND INTERLEUKIN-6 (IL-6) ON CEA AND CLASS I HLA EXPRESSION BY HUMAN COLON CARCINOMA CELLS (1993) (0)
Abstract A42: Phase I trial of EUS-guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer. (2012) (0)
Abstract 1230: Impact of apheresis (Aph) on number and function of lymphocytes in cancer patients (pts). (2013) (0)
Tumor Associated Antigens and Oncogene Products Defined by Monoclonal Antibodies (1987) (0)
Metformin for biochemical recurrence of prostate cancer: Immune data from a phase 2 study. (2023) (0)
Abstract 1260: Generation of human T cells directed against an agonist epitope of a transcription factor involved in epithelial to mesenchymal transition (EMT). (2013) (0)
Nucleic acid and protein studies of the Mason-Pfizer virus. (1975) (0)
Abstract B43: Simultaneous inhibition of CXCR1/CXCR2, TGF-β, and PD-L1 overcomes immune resistance driven by tumor plasticity (2020) (0)
Clinical T rial D esigns f or t he E arly C linical D evelopment of T herapeutic C ancer V accines (2001) (0)
TWO Therapeutic Cancer Vaccines (2014) (0)
Nouvelle famille d'anticorps chimeres diriges contre l'antigene carcino-embryonnaire (1994) (0)
Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells (2015) (0)
Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies (2019) (0)
Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. (2023) (0)
Randomized single institute pilot study of vaccinia-CEA(6D)-tricom and fowlpox-CEA (6D)-tricom with GM-CSF (V) in combination with docetaxel (D) in patients with colorectal cancer (CC). (2006) (0)
Abstract 1783: Distinctive effects of the Src-inhibitor, saracatinib (AZD0530), on T-cell activation and differentiation: A basic study to combine Src-inhibitor and vaccine based-cancer immunotherapy (2011) (0)
Increases the Ratio of T + Vaccine-Mediated Antigen-Specific CD 8 IL-2 / Anti-IL-2 Antibody Complex Enhances (2008) (0)
1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC) (2022) (0)
Biochemical Evidence for Viral Involvement in Human Breast Cancer (1975) (0)
Evaluation of TAG-72 and CEA tumor markers in sera of patients with gastrointestinal adenocarcinomas. (1990) (0)
296 Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors (2020) (0)
Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine (2023) (0)
Failure in Patients with Advanced Malignancy A Pilot Study of CTLA-4 Blockade after Cancer Vaccine (2007) (0)
Abstract LB-059: Neoadjuvant immunotherapy with androgen deprivation therapy (ADT) prior to radiation in prostate cancer: Impact on multiparametric prostate MRI and immune responses (2017) (0)
Abstract SY24-02: Development of recombinant vaccines for the prevention and therapy of human carcinomas (2011) (0)
Monoclonal Antibody B 72 . 3 Radioimmunoscintigraphy of Human Colon Cancer Xenografts in Mice with (2006) (0)
Diversified Prime and Boost Immunization Strategies (2003) (0)
Abstract B51: Circulating regulatory T-cell function and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated with vaccine. (2011) (0)
Biokinetics of a radioiodinated antibreast carcinoma monoclonal antibody and fragment in humans (1984) (0)
176 Vector-based Vaccines for Cancer Therapy (2009) (0)
This information is current as CTL Avidity Multiple Costimulatory Modalities Enhance (2005) (0)
Chimeric B 72 . 3 mouse / human ( IgG 1 ) antibody directs the lysis of tumor cells by lymphokine-activated killer cells (0)
An IL-15 superagonist enables anti-tumor efficacy of NK cells against all molecular variants of small cell lung cancer (SCLC). (2022) (0)
Optimization of an antibreast carcinoma monoclonal antibody as a tumor imaging agent (1984) (0)
Abstract 5540: Tumor phenotypic plasticity and resistance to immune-mediated cytotoxicity in models of castration resistant prostate cancer (2022) (0)
A MUTANT RAS MURINE CD8+ CTL PEPTIDE EPITOPE WITH ENHANCED IMMUNOGENICITY (1996) (0)
[In vivo application of monoclonal antibodies in the management of human carcinomas]. (1988) (0)
Abstract 1316: Evaluation of immune cell subsets of cancer patients treated with a fully human IgG1 anti-PD-L1 MAb (MSB0010718C) capable of mediating ADCC of human tumor cells (2015) (0)
Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12 (2023) (0)
Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression (2015) (0)
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. (2023) (0)
438 Interrogation of immune toxicity in patients with thymic epithelial tumors (TETs) (2022) (0)
Preparation of an immune response against prostat-specific antigen (PSA) (1996) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jeffrey Schlom?

Jeffrey Schlom is affiliated with the following schools:

Jeffrey Schlom's Academic­Influence.com Rankings

Jeffrey Schlom's Degrees

Why Is Jeffrey Schlom Influential?

Jeffrey Schlom's Published Works

Published Works

What Schools Are Affiliated With Jeffrey Schlom?

Jeffrey Schlom's AcademicInfluence.com Rankings